Inhibikase Therapeutics (IKT) EBT Margin (2020 - 2026)
Inhibikase Therapeutics (IKT) reported EBT Margin of -440356600.00% for Q4 2023, down 440349780.36 percentage points from -6819.64% a year earlier and down 440350606.62 percentage points from the prior quarter.
Inhibikase Therapeutics (IKT) EBT Margin (2020 - 2026) Analysis & Trends
For FY2023, Inhibikase Therapeutics posted EBT Margin of -7711.98%, up 6974.19 percentage points from FY2022.
- EBT Margin has a three-year change of -7304.25 percentage points (FY2020 to FY2023).
- By year, EBT Margin came in at -14686.17% in FY2022 (-14209.29 pp), -476.88% in FY2021 (-69.14 pp) and -407.73% in FY2020.
- The Q4 2023 figure ranks as the lowest quarterly EBT Margin in data going back to Q1 2020.
- Year over year, EBT Margin gained in four of the last eight quarters, with an average year-over-year change of -55014268.06 percentage points.
- The high point for year-over-year EBT Margin in five years was Q4 2022 (a gain of 252522.90 percentage points); the low point was Q4 2023 (a drop of 440349780.36 percentage points).
- Per Business Quant data, the three quarters before Q4 2023 came in at -5993.38% (Q3 2023), -5328.07% (Q2 2023) and -7307.62% (Q1 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,165.98 Bn | 1,134.57 Bn | 19.71 Bn | 40.25% |
| 2 | Johnson & Johnson | 643.66 Bn | 563.53 Bn | 17.30 Bn | 0.13% |
| 3 | AbbVie | 500.95 Bn | 474.06 Bn | 12.70 Bn | 25.18% |
| 4 | Merck | 358.08 Bn | 312.45 Bn | 12.21 Bn | -4.11% |
| 5 | Novartis Ag | 301.84 Bn | 265.83 Bn | 11.24 Bn | 29.63% |
| 6 | Astrazeneca | 267.25 Bn | 240.94 Bn | 12.86 Bn | 18.19% |
| 7 | Amgen | 241.42 Bn | 196.81 Bn | 7.24 Bn | 27.53% |
| 8 | Gilead Sciences | 193.09 Bn | 167.28 Bn | 6.22 Bn | -131.41% |
| 9 | Pfizer | 171.63 Bn | 118.27 Bn | 10.94 Bn | -4.34% |
| 10 | Inhibikase Therapeutics | 278.44 Mn | -307.03 Mn | - | -1,442.08% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,442.08% |
| Mar 31, 2026 | -1,221.15% |
| Dec 31, 2025 | -1,324.49% |
| Sep 30, 2025 | -1,521.86% |
| Jun 30, 2025 | -1,181.59% |
| Mar 31, 2025 | -1,588.00% |
| Dec 31, 2023 | -440,356,600.00% |
| Sep 30, 2023 | -5,993.38% |
| Jun 30, 2023 | -5,328.07% |
| Mar 31, 2023 | -7,307.62% |
| Dec 31, 2022 | -6,819.64% |
| Sep 30, 2022 | -61,645.36% |
| Jun 30, 2022 | -70,817.14% |
| Mar 31, 2022 | -10,081.47% |
| Dec 31, 2021 | -259,342.54% |
| Sep 30, 2021 | -1,361.26% |
| Jun 30, 2021 | -193.40% |
| Mar 31, 2021 | -187.40% |
| Dec 31, 2020 | -708.85% |
| Sep 30, 2020 | -1,779.72% |
Inhibikase Therapeutics EBT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebt-margin&ticker=IKT&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebt-margin", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ebt-margin&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();